Skip to main navigation
About Us
Overview
Leadership Team
Board of Directors
Our Programs
Pipeline
Livoletide
Nevanimibe
Disease Areas
Patients & Families
Our Commitment
Clinical Research Overview
Livoletide Pivotal Studies
Nevanimibe Clinical Studies
Educational Resources and Advocacy
Expanded Acces
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Corporate Governance
Annual Reports & SEC Filings
Investor Resources
Contact Us
Contact Information
Careers
Investor Relations
IR Contacts
Investor Resources menu
FAQs
IR Contact
E-mail Alerts
IR Contacts
Stephanie Ascher
Phone: 212-362-1200
E-mail:
stephanie@sternir.com
Shareholder Tools
Print Page
Email Page
RSS Feeds
E-mail Alerts
Financial Tear Sheet
